Literature DB >> 15533876

Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction.

Robert A Kloner1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15533876     DOI: 10.1161/01.CIR.0000146906.42375.D3

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  42 in total

Review 1.  Sexual activity and ischemic heart disease.

Authors:  Richard A Lange; Glenn N Levine
Journal:  Curr Cardiol Rep       Date:  2014-02       Impact factor: 2.931

2.  Recognition and management of complications during moderate and deep sedation. Part 2: cardiovascular considerations.

Authors:  Daniel E Becker; Daniel A Haas
Journal:  Anesth Prog       Date:  2011

Review 3.  The emerging role for type 5 phosphodiesterase inhibition in heart failure.

Authors:  Gregory D Lewis; Marc J Semigran
Journal:  Curr Heart Fail Rep       Date:  2006-09

Review 4.  Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure.

Authors:  Sevil Korkmaz-Icöz; Tamás Radovits; Gábor Szabó
Journal:  Br J Pharmacol       Date:  2017-03-23       Impact factor: 8.739

5.  An Observational Study to Evaluate the Prevalence of Erectile Dysfunction (ED) and Prescribing Pattern of Drugs in Patients with ED Visiting an Andrology Specialty Clinic, Mumbai: 2012-14.

Authors:  Amit S Mutha; Vijay R Kulkarni; Sagar B Bhagat; Amit S Beldar; Sadiq B Patel
Journal:  J Clin Diagn Res       Date:  2015-07-01

Review 6.  The Role of Nitroglycerin and Other Nitrogen Oxides in Cardiovascular Therapeutics.

Authors:  Sanjay Divakaran; Joseph Loscalzo
Journal:  J Am Coll Cardiol       Date:  2017-11-07       Impact factor: 24.094

7.  Management of complications during moderate and deep sedation: respiratory and cardiovascular considerations.

Authors:  Daniel E Becker; Daniel A Haas
Journal:  Anesth Prog       Date:  2007

8.  Effect of phospodiesterase 5 inhibitors on apoptosis and nitric oxide synthases in testis torsion: an experimental study.

Authors:  Hüseyin Ustün; K Turgay Akgül; Ali Ayyildiz; Hatice Yağmurdur; Bariş Nuhoğlu; Ersagun Karagüzel; Elmas Oğüş; Cankon Germiyanoğlu
Journal:  Pediatr Surg Int       Date:  2007-11-06       Impact factor: 1.827

Review 9.  The use of phosphodiesterase 5 inhibitors with concomitant medications.

Authors:  G Corona; E Razzoli; G Forti; M Maggi
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

Review 10.  Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors.

Authors:  H Al-Ameri; R A Kloner
Journal:  Int J Impot Res       Date:  2009-04-23       Impact factor: 2.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.